Vismodegib, a hedgehog (Hh) pathway inhibitor, is used to treat locally advanced or metastatic basal cell carcinoma (BCC) by blocking the activity of smoothened homolog (SMO), a key protein in the Hh pathway [65]. This evidence concerns the gene SMO and basal cell carcinoma.